Elsevier

The Lancet

Volume 298, Issue 7737, 11 December 1971, Pages 1273-1276
The Lancet

ORIGINAL ARTICLES
CONTROLLED TRIAL OF AZATHIOPRINE IN CROHN'S DISEASE

https://doi.org/10.1016/S0140-6736(71)90598-8Get rights and content

Abstract

The effect of azathioprine in patients with active Crohn's disease has been evaluated in a double-blind cross-over trial. Fifteen patients were treated with both azathioprine and placebo: only two improved while on azathioprine, six got worse, and in seven there was no change. The drug seemed to be the cause of deterioration in two of the patients. Although the drug may be of some value in a few patients, it should be used with caution and only when other measures have failed.

References (7)

  • B.N. Brooke et al.

    Lancet

    (1969)
  • B.N. Brooke et al.

    Lancet

    (1970)
  • J.M.T. Willoughby et al.

    Lancet

    (1971)
There are more references available in the full text version of this article.

Cited by (164)

  • Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis

    2018, Clinical Gastroenterology and Hepatology
    Citation Excerpt :

    Two antibiotics (ciprofloxacin and metronidazole) were evaluated in 1 study (n = 25).45 Thiopurines, including azathioprine and 6-mercaptopurine, were studied in 5 RCTs enrolling a total of 69 patients.30,33,36,37,46 Tacrolimus was evaluated in 1 primary study of CD fistula and 1 subgroup analysis (n = 58).29,40

  • Treatment algorithms in Crohn's - Up, down or something else?

    2014, Best Practice and Research: Clinical Gastroenterology
  • Reassessing the risks and benefits of thiopurines in crohn's disease

    2013, Clinical Gastroenterology and Hepatology
View all citing articles on Scopus
View full text